- Home
- FNA vs IMTX Comparison
FNA vs IMTX Comparison
Compare FNA & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNA
- IMTX
- Stock Information
- Founded
- FNA 2010
- IMTX N/A
- Country
- FNA United States
- IMTX Germany
- Employees
- FNA N/A
- IMTX N/A
- Industry
- FNA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FNA Health Care
- IMTX Health Care
- Exchange
- FNA Nasdaq
- IMTX Nasdaq
- Market Cap
- FNA 910.9M
- IMTX 954.2M
- IPO Year
- FNA 2021
- IMTX N/A
- Fundamental
- Price
- FNA $10.89
- IMTX $5.35
- Analyst Decision
- FNA Strong Buy
- IMTX Strong Buy
- Analyst Count
- FNA 5
- IMTX 4
- Target Price
- FNA $15.60
- IMTX $16.67
- AVG Volume (30 Days)
- FNA 533.4K
- IMTX 988.8K
- Earning Date
- FNA 02-27-2025
- IMTX 11-18-2024
- Dividend Yield
- FNA N/A
- IMTX N/A
- EPS Growth
- FNA N/A
- IMTX N/A
- EPS
- FNA N/A
- IMTX N/A
- Revenue
- FNA $244,995,000.00
- IMTX $128,824,447.00
- Revenue This Year
- FNA $18.58
- IMTX $116.22
- Revenue Next Year
- FNA $14.85
- IMTX N/A
- P/E Ratio
- FNA N/A
- IMTX N/A
- Revenue Growth
- FNA 18.16
- IMTX 52.53
- 52 Week Low
- FNA $4.65
- IMTX $5.28
- 52 Week High
- FNA $14.79
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- FNA 60.29
- IMTX 21.22
- Support Level
- FNA $10.11
- IMTX $7.00
- Resistance Level
- FNA $11.10
- IMTX $7.42
- Average True Range (ATR)
- FNA 0.61
- IMTX 0.41
- MACD
- FNA -0.04
- IMTX -0.14
- Stochastic Oscillator
- FNA 84.80
- IMTX 2.90
About FNA Paragon 28 Inc.
Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, Charcot, fracture fixation, hallux valgus, hammertoe, and flat foot. The company's suite of surgical solutions comprises nearly 80 product systems to help fit the specific needs of each patient and procedure. Geographically the company generates the majority of its revenue from the United States.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.